SCHEMBL3221382

SCHEMBL3221382

CSc1c(C#N)c(N)nc(SCc2coc(-c3ccc(Cl)cc3)n2)c1C#N

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 13/20 0.54
LMNA P02545 3/20 0.50
MAPT P10636 3/20 0.50
KDM4E B2RXH2 3/20 0.50
MAPK1 P28482 2/20 0.50
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
ALOX15 P16050 1/20 0.50
HTT P42858 1/20 0.50
HSD17B10 Q99714 1/20 0.50
NPSR1 Q6W5P4 2/20 0.49
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
RET P07949 1/20 0.45
SLC6A3 Q01959 1/20 0.43
ALDH1A1 P00352 2/20 0.41
HPGD P15428 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ADORA3 P0DMS8 1/20 0.41
ADORA2A P29274 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13429013 0.89 ADORA1 (0.48) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL16181819 0.85 KDM4E (0.58) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL13285072 0.83 ADORA1 (0.67) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL7998996 0.82 ADORA1 (0.51) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL2282429 0.81 ADORA1 (0.52) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL3231799 0.81 ADORA1 (0.53) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL13550204 0.80 MEN1 (0.53) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL7998995 0.80 ADORA1 (0.51) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL8006175 0.80 ADORA1 (0.51) ADORA1LMNAMAPTKDM4EMAPK1
SCHEMBL382420 0.80 ADORA1 (0.71) ADORA1SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703934-B2 Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-04-22 US disclosed
US-8703934-B2 Substituted 4-amino-3,5-dicyano-2-thiopyridines and use thereof BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-04-22 US disclosed
EP-2099781-B1 SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF BAYER IP GMBH (DE) 2012-10-24 EP disclosed
US-20100069363-A1 SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-03-18 US disclosed
US-20100069363-A1 SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-03-18 US disclosed
WO-2008064789-A1 SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069363-A1 SUBSTITUTED 4-AMINO-3,5-DICYANO-2-THIOPYRIDINES AND USE THEREOF QDPR, DDC, TPMT ADORA1 1199/4885LMNA 1969/4885MAPT 3170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.